没食子酸表没食子儿茶素酯在卵巢癌治疗中的潜在作用：现有知识状况。
The Potential Roles of Epigallocatechin-3-Gallate in the Treatment of Ovarian Cancer: Current State of Knowledge.
机构信息
Division of Anesthesia and Pain Medicine, Istituto Nazionale Tumori - IRCCS - "Fondazione G. Pascale, Naples, Italy.
出版信息
Drug Des Devel Ther. 2020 Oct 12;14:4245-4250. doi: 10.2147/DDDT.S253092. eCollection 2020.
Abstract
Ovarian cancer represents the principal leading cause of women dying in the world. The first standard of care involved surgical resection followed by chemotherapy with taxane and platinum, mainly connected with cytotoxic chemotherapies causing diverse severe side effects. Unfortunately, recurrence represents a significant problem, and finally, patients develop resistance to cytotoxic chemotherapy. Other alternative treatments had been developed so far to reduce side effects; however, the outcomes are yet not empowering. Current shreds of evidence showed that epigallocatechin-3-gallate (EGCG) possesses an anticancer effect on ovarian carcinoma, mainly through the inhibition of different genetic signaling pathways which are closely linked with tumorigenesis. This review recapitulates these findings and highlights the roles of EGCG for the chemoprevention and treatment of ovarian cancer.
摘要
卵巢癌是全球女性死亡的主要原因。标准的治疗方法是手术切除，然后进行紫杉醇和铂类药物的化疗，主要与细胞毒性化疗药物相关，会导致多种严重的副作用。不幸的是，复发是一个严重的问题，最终患者对细胞毒性化疗产生耐药性。到目前为止，已经开发了其他替代治疗方法来减少副作用，但结果还不尽如人意。目前的一些证据表明，表没食子儿茶素没食子酸酯 (EGCG) 对卵巢癌具有抗癌作用，主要通过抑制与肿瘤发生密切相关的不同基因信号通路。本综述总结了这些发现，并强调了 EGCG 在卵巢癌的化学预防和治疗中的作用。
相似文献
1
The Potential Roles of Epigallocatechin-3-Gallate in the Treatment of Ovarian Cancer: Current State of Knowledge.
Drug Des Devel Ther. 2020 Oct 12;14:4245-4250. doi: 10.2147/DDDT.S253092. eCollection 2020.
2
Protective Effects of Epigallocatechin Gallate (EGCG) on Endometrial, Breast, and Ovarian Cancers.
Biomolecules. 2020 Oct 25;10(11):1481. doi: 10.3390/biom10111481.
3
Anticancer effects of (-)-epigallocatechin-3-gallate on ovarian carcinoma cell lines.
Gynecol Oncol. 2004 Sep;94(3):760-8. doi: 10.1016/j.ygyno.2004.05.031.
4
Bioinformatics Analysis on Molecular Mechanism of Green Tea Compound Epigallocatechin-3-Gallate Against Ovarian Cancer.
Clin Transl Sci. 2017 Jul;10(4):302-307. doi: 10.1111/cts.12470. Epub 2017 May 23.
5
Effects of epigallocatechin gallate, epigallocatechin and epicatechin gallate on the chemical and cell-based antioxidant activity, sensory properties, and cytotoxicity of a catechin-free model beverage.
Food Chem. 2021 Mar 1;339:128060. doi: 10.1016/j.foodchem.2020.128060. Epub 2020 Sep 11.
6
A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer.
Gynecol Oncol. 2013 Nov;131(2):357-61. doi: 10.1016/j.ygyno.2013.08.019. Epub 2013 Aug 27.
7
Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma.
Mol Cancer Ther. 2006 Jun;5(6):1483-92. doi: 10.1158/1535-7163.MCT-06-0053.
8
The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression.
J Ethnopharmacol. 2020 Oct 28;261:113118. doi: 10.1016/j.jep.2020.113118. Epub 2020 Jul 1.
9
Potential Therapeutic Targets of Epigallocatechin Gallate (EGCG), the Most Abundant Catechin in Green Tea, and Its Role in the Therapy of Various Types of Cancer.
Molecules. 2020 Jul 9;25(14):3146. doi: 10.3390/molecules25143146.
10
Epigallocatechin gallate hinders human hepatoma and colon cancer sphere formation.
J Gastroenterol Hepatol. 2016 Jan;31(1):256-64. doi: 10.1111/jgh.13069.
引用本文的文献
1
In silico docking, ADMET profiling, and bio-accessibility experimentation on phytocompounds and in vitro validation for anti-proliferative potencies against ovarian carcinoma.
3 Biotech. 2025 May;15(5):121. doi: 10.1007/s13205-025-04276-8. Epub 2025 Apr 10.
2
Role of Epigallocatechin Gallate in Selected Malignant Neoplasms in Women.
Nutrients. 2025 Jan 8;17(2):212. doi: 10.3390/nu17020212.
3
Pre-diagnosis tea and coffee consumption and survival after a diagnosis of ovarian cancer: results from the Ovarian Cancer Association Consortium.
Br J Cancer. 2024 Oct;131(6):1043-1049. doi: 10.1038/s41416-024-02792-7. Epub 2024 Jul 18.
4
Epigallocatechin Gallate for the Treatment of Benign and Malignant Gynecological Diseases-Focus on Epigenetic Mechanisms.
Nutrients. 2024 Feb 17;16(4):559. doi: 10.3390/nu16040559.
5
Podophyllotoxin: Recent Advances in the Development of Hybridization Strategies to Enhance Its Antitumoral Profile.
Pharmaceutics. 2023 Dec 4;15(12):2728. doi: 10.3390/pharmaceutics15122728.
6
Epigallocatechin gallate inhibits ovarian cancer cell growth and induces cell apoptosis via activation of FOXO3A.
In Vitro Cell Dev Biol Anim. 2023 Dec;59(10):739-746. doi: 10.1007/s11626-023-00830-x. Epub 2023 Dec 1.
7
The Effects of Natural Epigenetic Therapies in 3D Ovarian Cancer and Patient-Derived Tumor Explants: New Avenues in Regulating the Cancer Secretome.
Biomolecules. 2023 Jul 1;13(7):1066. doi: 10.3390/biom13071066.
8
Regioselective Synthesis of Quercetin and Myricetin Derivatives.
Russ J Gen Chem. 2023;93(2):245-252. doi: 10.1134/S1070363223020032. Epub 2023 Mar 30.
9
Possible Side Effects of Polyphenols and Their Interactions with Medicines.
Molecules. 2023 Mar 10;28(6):2536. doi: 10.3390/molecules28062536.
10
An Overview on the Potential Roles of EGCG in the Treatment of COVID-19 Infection.
Drug Des Devel Ther. 2021 Oct 28;15:4447-4454. doi: 10.2147/DDDT.S314666. eCollection 2021.
本文引用的文献
1
Current shreds of evidence on the anticancer role of EGCG in triple negative breast cancer: an update of the current state of knowledge.
Infect Agent Cancer. 2020 Jan 10;15:2. doi: 10.1186/s13027-020-0270-5. eCollection 2020.
2
Shining a Light on the Effects of the Combination of (-)-Epigallocatechin-3-gallate and Tapentadol on the Growth of Human Triple-negative Breast Cancer Cells.
In Vivo. 2019 Sep-Oct;33(5):1463-1468. doi: 10.21873/invivo.11625.
3
Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review.
Diagnostics (Basel). 2019 Aug 1;9(3):87. doi: 10.3390/diagnostics9030087.
4
PARP Inhibitors in Ovarian Cancer: The Route to "Ithaca".
Diagnostics (Basel). 2019 May 18;9(2):55. doi: 10.3390/diagnostics9020055.
5
Epigallocatechin-3-gallate inhibits doxorubicin-induced inflammation on human ovarian tissue.
Biosci Rep. 2019 May 14;39(5). doi: 10.1042/BSR20181424. Print 2019 May 31.
6
Epigallocatechin-3-gallate in the prevention and treatment of hepatocellular carcinoma: experimental findings and translational perspectives.
Drug Des Devel Ther. 2019 Feb 12;13:611-621. doi: 10.2147/DDDT.S180079. eCollection 2019.
7
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
8
Epigallocatechin-3-gallate enhances ER stress-induced cancer cell apoptosis by directly targeting PARP16 activity.
Cell Death Discov. 2017 Jul 10;3:17034. doi: 10.1038/cddiscovery.2017.34. eCollection 2017.
9
An overview of pre-clinical studies on the effects of (-)-epigallocatechin-3-gallate, a catechin found in green tea, in treatment of pancreatic cancer.
Recenti Prog Med. 2017 Jun;108(6):282-287. doi: 10.1701/2715.27715.
10
Bioinformatics Analysis on Molecular Mechanism of Green Tea Compound Epigallocatechin-3-Gallate Against Ovarian Cancer.
Clin Transl Sci. 2017 Jul;10(4):302-307. doi: 10.1111/cts.12470. Epub 2017 May 23.
Zotero 插件